A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Male and female participants aged 19 years or older.
• Patients diagnosed with acute bronchitis with:
‣ A Bronchitis Severity Score (BSS) of ≥ 5 at Visit 2.
⁃ A sputum subscore of at least 1 at Visit 2.
• Onset of acute bronchitis symptoms within 48 hours prior to Visit 2.
• Patients who voluntarily agree to participate
Locations
Other Locations
Republic of Korea
Konkuk University Medical Center
RECRUITING
Seoul
Contact Information
Primary
KyoungHee Jung
khjung@arlico.co.kr
+82-2-520-6948
Time Frame
Start Date: 2025-04-23
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 168
Treatments
Experimental: Experimental Group 1
Experimental: Experimental Group 2
Active_comparator: Active Comparator Group
Placebo_comparator: Placebo Comparator Group
Related Therapeutic Areas
Sponsors
Leads: Korea Arlico Pharm. Co., Ltd